• Raffaele Marfella, Celestino Sardu, Nunzia D'Onofrio, Carlo Fumagalli, Lucia Scisciola, Ferdinando Carlo Sasso, Mario Siniscalchi, Ludovica Vittoria Marfella, Davide D'Andrea, Fabio Minicucci, Giuseppe Signoriello, Arturo Cesaro, Maria Consiglia Trotta, Chiara Frigé, Francesco Prattichizzo, Maria Luisa Balestrieri, Antonio Ceriello, Paolo Calabrò, Ciro Mauro, Luca Del Viscovo, and Giuseppe Paolisso.
• Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy. raffaele.marfella@unicampania.it.
• Bmc Med. 2023 Feb 24; 21 (1): 7171.

BackgroundNo study evaluated the incidence of intra-stent restenosis (ISR)-related events in patients with type 2 diabetes (T2DM) and acute myocardial infarction (AMI) treated or not with sodium/glucose cotransporter 2 inhibitors (SGLT2i).MethodsWe recruited 377 patients with T2DM and AMI undergoing percutaneous coronary intervention (PCI). Among them, 177 T2DM were treated with SGLT2 inhibitors before PCI. The primary outcome was major adverse cardiovascular events (MACE) defined as cardiac death, re-infarction, and heart failure related to ISR. In patients without ISR, minimal lumen area and minimal lumen diameter were assessed by coronary CT-angiography at 1-year follow-up.ResultsGlycemic control was similar in SGLT2i-treated patients and never SGLT2i-users. The incidence of ISR-related MACE was higher in never SGLT2i-users compared with SGLT2i-treated patients, an effect independent of glycemic status (HR = 0.418, 95% CI = 0.241-0.725, P = 0.002) and observed also in the subgroup of patients with HbA1c < 7% (HR = 0.393, 95% CI = 0.157-0.984, P = 0.027). In patients without the event, the stent patency was greater in SGLT2i-treated patients compared with never SGLT2i-users at 1-year follow-up.ConclusionsSGLT2i treatment in T2DM is associated with a reduced incidence of ISR-related events, independently of glycemic control.© 2023. The Author(s).

19 keywords...

hide…